JP5049139B2 - 内臓痛を治療するためのオキシコドンの使用 - Google Patents

内臓痛を治療するためのオキシコドンの使用 Download PDF

Info

Publication number
JP5049139B2
JP5049139B2 JP2007550797A JP2007550797A JP5049139B2 JP 5049139 B2 JP5049139 B2 JP 5049139B2 JP 2007550797 A JP2007550797 A JP 2007550797A JP 2007550797 A JP2007550797 A JP 2007550797A JP 5049139 B2 JP5049139 B2 JP 5049139B2
Authority
JP
Japan
Prior art keywords
oxycodone
pain
formulation
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007550797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526927A5 (enExample
JP2008526927A (ja
Inventor
モーア ドレベス，アズビエルン
アレント ニェルセン，ラース
Original Assignee
ユーロ−セルティーク エス．エイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5049139(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ユーロ−セルティーク エス．エイ． filed Critical ユーロ−セルティーク エス．エイ．
Publication of JP2008526927A publication Critical patent/JP2008526927A/ja
Publication of JP2008526927A5 publication Critical patent/JP2008526927A5/ja
Application granted granted Critical
Publication of JP5049139B2 publication Critical patent/JP5049139B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2007550797A 2005-01-18 2006-01-17 内臓痛を治療するためのオキシコドンの使用 Expired - Fee Related JP5049139B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
US60/645,490 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Publications (3)

Publication Number Publication Date
JP2008526927A JP2008526927A (ja) 2008-07-24
JP2008526927A5 JP2008526927A5 (enExample) 2009-02-05
JP5049139B2 true JP5049139B2 (ja) 2012-10-17

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007550797A Expired - Fee Related JP5049139B2 (ja) 2005-01-18 2006-01-17 内臓痛を治療するためのオキシコドンの使用

Country Status (31)

Country Link
US (2) US20080200493A1 (enExample)
EP (1) EP1838318B1 (enExample)
JP (1) JP5049139B2 (enExample)
KR (10) KR20200128451A (enExample)
CN (1) CN101106996B (enExample)
AP (1) AP2249A (enExample)
AR (1) AR052880A1 (enExample)
AT (2) ATE446092T1 (enExample)
AU (1) AU2006207498B2 (enExample)
BR (1) BRPI0606247A2 (enExample)
CA (1) CA2595043C (enExample)
CY (1) CY1109660T1 (enExample)
DE (2) DE602006009899D1 (enExample)
DK (2) DK1838318T3 (enExample)
EA (1) EA013544B1 (enExample)
ES (1) ES2333901T3 (enExample)
HR (1) HRP20090679T1 (enExample)
IL (1) IL184530A (enExample)
ME (1) ME01066B (enExample)
MX (1) MX2007007207A (enExample)
MY (1) MY144471A (enExample)
NO (1) NO338968B1 (enExample)
NZ (1) NZ555852A (enExample)
PL (1) PL1838318T3 (enExample)
PT (1) PT1838318E (enExample)
RS (1) RS51069B (enExample)
SI (1) SI1838318T1 (enExample)
TW (1) TWI432196B (enExample)
UA (1) UA85471C2 (enExample)
WO (1) WO2006077212A1 (enExample)
ZA (1) ZA200705231B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3045182T3 (en) 2005-11-14 2018-03-19 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
RU2535074C2 (ru) * 2009-08-28 2014-12-10 Лэйбрис Байолоджикс, Инк. Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
TWI692485B (zh) 2011-05-20 2020-05-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
CN103702685B (zh) 2011-05-20 2017-12-15 奥尔德生物控股有限责任公司 抗cgrp抗体和抗体片段用于在有需要的受试者、尤其是偏头痛患者中预防或抑制畏光或厌光的用途
KR102128628B1 (ko) 2011-05-20 2020-06-30 앨더바이오 홀딩스 엘엘씨 설사의 만성 및 급성 형태를 치료 또는 예방하기 위한 항-cgrp 또는 항-cgrp-r 항체 또는 항체 단편의 용도
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
RS65360B1 (sr) 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
JP7472116B2 (ja) 2018-11-19 2024-04-22 ジャズ ファーマシューティカルズ アイルランド リミテッド 耐アルコール性製剤
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
SG10202003296VA (en) 2020-04-06 2021-11-29 H Lundbeck As Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
RS51069B (sr) 2010-10-31
KR20200128451A (ko) 2020-11-12
DK200700207U3 (da) 2007-09-28
CN101106996B (zh) 2013-10-23
KR20120089710A (ko) 2012-08-13
HK1107933A1 (en) 2008-04-25
UA85471C2 (ru) 2009-01-26
CA2595043C (en) 2013-11-19
MY144471A (en) 2011-09-30
DK200700207U1 (da) 2007-08-24
DK1838318T3 (da) 2010-01-04
US20080200493A1 (en) 2008-08-21
KR20230170811A (ko) 2023-12-19
NO338968B1 (no) 2016-11-07
ATE446092T1 (de) 2009-11-15
US9271974B2 (en) 2016-03-01
NO20074174L (no) 2007-10-17
ES2333901T3 (es) 2010-03-02
KR20070100368A (ko) 2007-10-10
PT1838318E (pt) 2009-12-15
EP1838318B1 (en) 2009-10-21
US20150190393A1 (en) 2015-07-09
DE602006009899D1 (de) 2009-12-03
SI1838318T1 (sl) 2010-02-26
ME01066B (me) 2012-10-20
IL184530A0 (en) 2007-10-31
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
NZ555852A (en) 2010-01-29
TWI432196B (zh) 2014-04-01
EA200701541A1 (ru) 2008-02-28
HRP20090679T1 (hr) 2010-01-31
AP2007004057A0 (en) 2007-08-31
AT9895U1 (de) 2008-05-15
KR20190135557A (ko) 2019-12-06
CA2595043A1 (en) 2006-07-27
EP1838318A1 (en) 2007-10-03
CY1109660T1 (el) 2014-08-13
KR20080106991A (ko) 2008-12-09
WO2006077212A1 (en) 2006-07-27
AU2006207498A1 (en) 2006-07-27
AP2249A (en) 2011-07-18
DE202006019887U1 (de) 2007-07-26
IL184530A (en) 2015-01-29
AR052880A1 (es) 2007-04-11
CN101106996A (zh) 2008-01-16
JP2008526927A (ja) 2008-07-24
BRPI0606247A2 (pt) 2009-06-09
AU2006207498B2 (en) 2009-11-19
PL1838318T3 (pl) 2010-03-31
ZA200705231B (en) 2008-06-25
KR20220165797A (ko) 2022-12-15
KR20140091782A (ko) 2014-07-22
TW200637554A (en) 2006-11-01
KR20210131450A (ko) 2021-11-02
EA013544B1 (ru) 2010-06-30

Similar Documents

Publication Publication Date Title
US9271974B2 (en) Use of oxycodone for treating visceral pain
KR20070107805A (ko) 옥시코돈 및 날록손 함유 제형
ES3036967T3 (en) Delayed release deferiprone tablets and methods of using the same
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
US20210113537A1 (en) Combination therapies for the treatment of breast cancer
WO2015071380A1 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
JP6723229B2 (ja) アルペリシブを含む医薬組成物
HK1107933B (en) Use of oxycodone for treating visceral pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120313

TRDD Decision of grant or rejection written
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120605

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120626

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120720

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150727

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees